Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2010

View Archived Issues

GSK-1521498 reduces hedonistic eating behavior in overweight/obese subjects

Several phase II trials support safety and tolerability of BMS-708163 in healthy subjects

Sexual dysfunction in schizophrenia linked to typical antipsychotics, prolactin and DRD2 genotype

Scientists find new oncolytic virus sensitizers showing potential in cancer therapy

Astaxanthin derivatives show promise in preclinical models of cardiovascular inflammation

Intra-Cellular Therapies reports phase Ib/II data on ITI-007 in schizophrenia

Charles River Laboratories and WuXi PharmaTech terminate acquisition agreement

First patients with hepatitis C achieve SVR in phase II ANA-528 trial

Daiichi Sankyo and Kitasato Institute to form joint venture company

Harvard College claims new fluorinated compounds

New phase III pimavanserin trial begins in Parkinson's disease psychosis

German scientists discover new nitric oxide donors/arginase inhibitors

GlaxoSmithKline discloses new NS5B inhibitors

FDA lifts hold on Geron's IND application for GRNOPC1 ESC-based therapy

National Eye Institute awards Lpath grant to develop sonepcizumab for wet AMD

Auspex Pharma presents new deuterated clozapine derivatives

FDA advises of adverse effects related to unintended exposure to Evamist

Daiichi Sankyo discovers novel CaS receptor antagonists

Actient Pharmaceuticals acquires six pharmaceuticals from UCB

Update on Fluvax seasonal influenza vaccine

Abraxane is approved in New Zealand for metastatic breast cancer

Novartis begins phase I trial of HuCAL-derived antibody

Stellar Pharma and Inibsa sign agreement to distribute and sell Uracyst in Spain

Curaxis Pharmaceutical merges with Auto Search Cars

Icagen and Pfizer begin first-in-human trial in sodium channel program for pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...